Key points
- There are currently no dengue vaccines available in the United States.
- Globally, several dengue vaccines have been approved or are in different stages of development.
- People can continue to protect themselves and their families from dengue by preventing mosquito bites and controlling mosquitoes in and around their homes.
Overview
An ideal dengue vaccine would provide long-lasting protection against all four dengue viruses (DENV-1–4). People can get sick from dengue multiple times if they are infected by different dengue viruses. The dengue vaccines that have been evaluated to date have provided stronger protection in people who had a previous DENV infection compared to people without a previous DENV infection. The vaccines have also shown different levels of protection against the different DENVs.
Encourage patients to continue to protect themselves and their families from dengue by preventing mosquito bites and controlling mosquitoes in and around their homes.
Dengvaxia
Dengvaxia was a discontinued live-attenuated dengue vaccine that required three doses. It was recommended for children aged 9–16 years with laboratory-confirmed previous DENV infection living in areas of the United States where dengue is endemic. In 2024, the manufacturer, Sanofi-Pasteur, announced that Dengvaxia would be discontinued due to a lack of demand in the global market. Dengvaxia is no longer available in the United States.
Qdenga
Qdenga is a live-attenuated dengue vaccine manufactured by Takeda. The vaccine requires two doses given 3 months apart. Qdenga has been authorized for use in more than 40 countries, including Argentina, Brazil, Indonesia, and Thailand. In 2023, the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunization recommended the vaccine for use in children aged 6–16 in settings with high dengue transmission intensity.
In 2023, the manufacturer voluntarily withdrew Qdenga's vaccine application for approval to the U.S. Food and Drug Administration, and Qdenga is not available or recommended for use in the United States.
TV003
TV003 is a single-dose dengue vaccine developed by the U.S. National Institutes of Health. It has been licensed to several manufacturers globally, including Merck & Co in the United States and the Instituto Butantan in Brazil.
In 2024, preliminary results from the phase 3 trial in Brazil showed that the overall efficacy against virologically confirmed dengue after 3.7 years was 77% among seropositive people (with previous DENV infection) and 60% among seronegative people.
In December 2025, Butantan-DV was approved for use in Brazil among individuals 12–59 years old. However, in June 2026 the Brazilian Ministry of Health temporarily suspended use of the dengue vaccine while they investigate adverse event reports.
Several other dengue vaccines or dengue vaccine models are being evaluated in clinical trials and ongoing research studies.
This page was last updated on this date. Updates may include minor edits, image changes, or other modifications to page content.
The information on this page was last reviewed by subject matter experts to ensure accuracy.